ISARIC COVID-19

What are the sequelae of COVID-19? Join our COVID-19 clinical trial study and help find the consequences of this disease!


Collaborate and participate with us!

Sites are welcome to download the open-access patient data collection and consent form as well as the protocol to contribute to combined analysis to forward knowledge into COVID-19.

Description of the Study:

  • Title: ISARIC Global COVID-19 Long term Follow up Study.
  • Principal Investigator: Louise Sigfrid.
  • Co-Investigators: John Amuasi, Fernando Bozza, Ibrahim Richard Bangura, Anders Benjamin Kildal, Jan Cato Holter, Antonia Ho, Lance Turtle, Clark Russell, Jordi Rello, Daniel Munblit, Anne Margarita Dyrholt-Riise, Carlo Palmieri, Edwin Jesudason, Wei Shen Lim, Muge Cevik, Tom Drake, Katrina Hann, Anna Beltrame, Madiha Hashmi, Sulaiman Lakoh, Jo McPeake, Colin Berry, David Lowe, Natalie Elkheir and Janet Scott.
  • Center of Implementation: Multicentric.
  • Study Population:  It will enroll patients following a diagnosis of COVID-19.  
  • Study Type: International prospective and observational multi-site study.
  • Design: Patients diagnosed with COVID-19. They will be separated into two different groups:
    1. Level 1, which will be developed follow up patients day 28 post-discharge (0/2-3 months). Additionally, depending on need and resources, they will also be followed up at 3 to 6 months intervals up to 3 to 5 years, depending on need and resources. Modules of this level can serve to identify subsets of patients experiencing specific symptomatology or syndromes for further follow-up.
    2. Level 2 modules, will be developed for further in-clinic, in-depth follow-up of a subset of patients experiencing persistent symptomatology.

Objectives of the Study:

Principal Objective: Characterise physical and psychosocial consequences in patients post-COVID-19. 

Secondary Objective: Stimate the frequency and risk factors for post-COVID-19 medical sequelae, psychosocial consequences, and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer-term antibody and cell-mediated immune responses to SARS-CoV-2.

More about this Study:

Scientific Context: Very little is known about possible clinical sequelae that may persist after resolution of the acute COVID-19.

However, a recent longitudinal cohort from Italy, including 143 patients who recovered after hospitalization with COVID-19, reported that 87% had at least one ongoing symptom at 60-day follow-up.

In fact, early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. Nevertheless, the assessment of risk factors for longer-term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of the illness.

Hence, the ISARIC Global COVID-19 follow-up working group has, in collaboration with a range of experts, developed a protocol and a patient survey to assess the long-term health and psychosocial consequences of COVID-19.

Don’t hesitate to join this covid-19 clinical trial study and help find out the consequences of this disease!

ISARIC leads this COVID-19 clinical trial study about the consequences of the disease.

Other Clinical Trials:

Un bain de bouche antiviral et COVID-19

L'utilisation d'un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2…

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l'évolution de la réponse immunitaire dans les mois qui suivent l'infection par le SARS-CoV-2 chez les hommes…

COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d'une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l'air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of…

Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of…

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer's COVID vaccine in children under 12 years of age.